

Catalog # 10-2868 Purvalanol A

CAS# 212844-53-6

(2R)-2-[[6-[(3-Chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol NG-60

Lot # X101452

Cyclin-dependent kinase inhibitor. IC₅₀s= 4, 70, 35, 75 and 850 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk5/p35 and cdk4/cyclin D1 and respectively. Reversibly arrests synchronized cells in G1 and G2 phase. Induces ER stress-mediated apoptosis and autophagy in colon cancer cells. Suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. In cells transformed with MYC, purvalanol A rapidly down-regulates survivin expression and induces MYC-dependent apoptosis. Cell permeable.

- 1) Gray et al. (1998), Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors; Science, 281 533
- 2) Villerbu et al. (2002), Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities; Int. J. Cancer, 97 761
- 3) Coker-Gurkan et al. (2015), Purvalanol induces endoplasmic reticulum stress-mediated apoptosis and autophagy in a time dependent manner in HCT116 colon cancer cells; Oncol. Rep., 33 2761
- 4) Hikita et al. (2010), Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src; Genes Cells, **15** 1051
- 5) Goga et al. (2007), Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC; Nat. Med., 13 820

PHYSICAL DATA

Molecular Weight: 388.89

Molecular Formula: C₁₉H₂₅ClN₆O Purity: 98% by HPLC

NMR: (Conforms)

Solubility: DMSO (up to 35 mg/ml)

Physical Description: Pale green solid

Storage and Stability: Store as supplied desiccated at -20°C for up to 1 year from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 2 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.